4D Molecular Therapeutics, Inc. Common Stock Morgan Stanley 24th Annual Global Healthcare Conference

Sure. David Kirn, founder and CEO. It is good to see you. Thanks for having us. Yeah, we are bringing next-generation gene therapy to large markets. We think that makes us pioneers in the gene therapy space, and we can do that because we have used directed evolution to invent highly optimized vectors, which allow us to overcome the hurdles with traditional gene therapy, and that is bring down the doses, lower cost of goods, better safety profile, better efficacy profile. Our lead product is 4D-150. It is for neovascular diseases of the retina, starting with wet AMD and moving on to diabetic macular edema.

and ultimately to diabetic retinopathy. Then we have a pipeline of products behind that in both retina and lung.

Chris, you want to speak to that?

Yeah. As David referenced, 4D-150 is the lead asset of looking at wet AMD as the first indication.

I think the history of this space, retinal disease of wet AMD and DME in particular, has been driven by bolus anti-VEGF therapeutics, which have been highly efficacious, at least in terms of providing initial vision benefit. The challenge has been historically that these therapies are delivered intravitreal, so a needle in the eye at some rate or frequency dependent upon the patient.

And that, of course, creates treatment burden. It's hard for patients to stay on therapy despite gaining vision on these therapies. So what a lot of companies have endeavored to do is to increase the durability of their medicines so that they can therefore reduce that treatment burden need on patients, physicians, and their caregivers. And that durability quest, if you will, has been met by incremental benefit Okay I mean, incremental changes.

You see drugs like EYLEA HD or VABYSMO, where they can extend that durability by a number of weeks. Maybe it results in one less injection per year. That's been meaningful. Those medicines have become very successful from a commercial perspective. However, we think the ultimate goal here would be could you not just extend durability by a couple of weeks, but could you actually push it by months or years, or maybe even the lifetime- Right for a patient.

We think a gene therapy modality, provided that it's safe- has the potential to do that.

I think the unique thing about the science from 4DMT is that we have shown the ability to produce very selective vectors- which we think have a connection to the safety of the medicine.

We think that underpins why R100, which is the vector for 4D-150, is very unique. It gave us great interest in going into mass market retinal disease with 4D-150 to accomplish just that. We think we have the possibility of not just affecting durability by a number of weeks, but maybe doing it by orders of magnitude, months, years.

In addition, potentially in doing so, also allow a patient to maintain their vision for years to come. That, we think, is paradigm shifting for patients and for the overall therapy area.